Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ensysce Biosciences Inc ENSCW


Primary Symbol: ENSC

Healthcare Biotechnology
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology... see more

Recent & Breaking News (NDAQ:ENSC)

Ensysce Biosciences Announces First Patients Enrolled in Phase 1 Study of PF614-MPAR(TM), its unique technology platform to provide opioid overdose protection

GlobeNewswire December 15, 2021

Ensysce Biosciences Announces Clinical Trial Progress of its New Class of Opioids

GlobeNewswire November 30, 2021

Ensysce Biosciences Reports Third Quarter 2021 Financial Results and Recent Corporate Updates

GlobeNewswire November 15, 2021

Ensysce Biosciences Announces Completion of $15 Million Convertible Note Financing

GlobeNewswire November 8, 2021

Ensysce Biosciences Grows its Management Team with Appointment of Dr. Linda Pestano as Chief Development Officer

GlobeNewswire October 26, 2021

Ensysce Biosciences Announces $15 Million Convertible Note Financing

GlobeNewswire September 27, 2021

Ensysce Biosciences Announces Treatment of First Cohort for Subjects in Clinical Study of its Next Generation Opioid, PF614

GlobeNewswire September 8, 2021

Ensysce Biosciences Sets September 2021 Conference Schedule

Accesswire August 31, 2021

Ensysce Biosciences to Host Satellite Symposium with Dr. Jeffrey Gudin at PAINWeek 2021 on September 9, 2021

GlobeNewswire August 19, 2021

Ensysce Biosciences Reports Second Quarter 2021 Financial Results and Recent Corporate Updates

GlobeNewswire August 16, 2021

Ensysce Biosciences Announces Notice of Allowance from the U.S. Patent and Trademark Office for Patent Entitled "Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof"

GlobeNewswire August 5, 2021

Ensysce Biosciences Bolsters Management Team with Appointments of David J. Kovacs as VP Public Policy and David Tanzer as VP Strategic Development

GlobeNewswire July 26, 2021

Ensysce Biosciences to Host Virtual Investor Day on July 27, 2021

GlobeNewswire July 21, 2021

Ensysce Biosciences Receives Notice of Award for Year Three of Multi-Year NIDA Grant for the Clinical Development of its Next Generation Opioid Products with Overdose Protection

GlobeNewswire July 8, 2021

Ensysce Biosciences to Begin Trading its Common Stock on The Nasdaq Capital Market on July 2, 2021

GlobeNewswire July 1, 2021

Ensysce Biosciences to Commence Trading on the OTC on July 1, 2021

GlobeNewswire June 30, 2021

Leisure Acquisition Corp. Announces Receipt of and Plan to Appeal Nasdaq Listing Determination

PR Newswire June 1, 2021

Ensysce Biosciences' Covistat Subsidiary "At Home Coronavirus Pill" Commencing to Phase 2 clinical development

GlobeNewswire May 7, 2021

Ensysce Biosciences Receives Investigational New Drug Allowance for its Unique PF614-MPAR(TM) Opioid with Overdose Protection

GlobeNewswire April 29, 2021

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigation of Mergers

GlobeNewswire March 16, 2021